Glucagon augments the secretion of FGF21 and GDF15 in MASLD by indirect mechanisms
{{output}}
Introduction: Glucagon receptor agonism is currently explored for the treatment of obesity and metabolic dysfunction-associated steatotic liver disease (MASLD). The metabolic effects of glucagon receptor agonism may in part be me... ...
